Lupin gets nod to enter into business transfer agreement with LMSL

12 Sep 2023 Evaluate

Lupin has received approval from board of directors to enter into a business transfer agreement with Lupin Manufacturing Solutions (LMSL), wholly owned subsidiary of the Company, to carve out two Active Pharmaceutical Ingredients (‘API’) manufacturing sites at Dabhasa and Visakhapatnam and select R&D operations, including fermentation, at Lupin Research Park, Pune. The consideration expected to be received is Rs 750.00 – Rs 850.00 crore, subject to movement in working capital and other items in the intervening period up to completion. The Board of Directors at its meeting held on September 11, 2023 has approved the same. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2105.85 2.55 (0.12%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×